Platinum Program Portfolio

Accelerating Success

Beech Biotech

Beech Biotech is unlocking novel biology to create breakthrough treatments for preeclampsia and other complications of pregnancy. We are developing “Mother only” monoclonals, medicines that can treat the mother, without affecting her baby.

Enodia Therapeutics

Enodia Therapeutics is a French biotech company building a proprietary small-molecule platform that selectively modulates the SEC61 translocon, a central control point of the protein secretion pathway.

SparkSeven Bio

SparkSeven utilizes a proprietary discovery platform to develop antibody-based therapies for cardiometabolic diseases.

Orb Therapeutics

Orb Therapeutics is developing next-generation precision medicines for genetically defined diseases. The company combines deep biology, chemistry and computational design to discover and advance a pipeline of novel therapeutics.

ImmunoBiochem

ImmunoBiochem is developing degrader-antibody conjugate (DAC) therapeutics, integrating the precision of antibodies with the catalytic power of targeted protein degraders. Capable of accessing therapeutic targets both on the cell surface and intracellularly, ImmunoBiochem’s DACs are engineered to unlock unique mechanisms of action in immunology and neuroimmunology to enable selectivity and efficacy beyond the reach of other modalities.

Switchback Therapeutics

Switchback is an engine for bispecific antibodies addressing unmet needs in autoimmune and inflammatory diseases. Their AI Operating System closes the loop from novel combinatorial biology to efficient Proof of Concept.

Stellaris Biosciences

Stellaris Biosciences is developing antibody-based degraders to eliminate autoimmune disease at its root cause, with precision.

Amplify Therapeutics

Amplify Therapeutics ApS is a lysosome-biology focused company based on deploying our extensive expertise and network in lysosomal biology and successful track record of cost-effectively developing approved lysosomal disease drugs (Miplyffa™). Our lead program targets diseases with genetically validated lysosomal dysfunction such as lysosomal storage diseases and lysosomal Parkinson's disease. It is based on a novel way to safely amplify lysosomal biogenesis and autophagy through modulation of a clinically derisked target.

Skape Bio

Skape Bio is designing miniprotein therapeutics that unlock G protein-coupled receptors (GPCRs) and other challenging drug targets that have remained out of reach.

Seen Therapeutics

Seen Therapeutics is uncovering a hidden world of tumor-specific antigens and engineering antibody-driven medicines to precisely target them. Using advanced structural and computational proteomics, Seen reveals cancer-specific features invisible to conventional discovery methods to create more selective and effective therapies.

ResNovas Therapeutics

ResNovas is a preclinical-stage biotech developing novel therapeutic approaches for highly validated but historically undruggable targets in oncology and beyond.

State 4 Therapeutics

State 4 Therapeutics is developing once-daily oral therapies designed to work synergistically with incretins to promote durable, high-quality weight loss and metabolic health improvements.

Laurel Biotherapeutics

Laurel Biotherapeutics is developing next-generation antibody therapeutics targeting pathways in cardiovascular dysfunction, inflammation, and metabolism

Overture Therapeutics

Overture Therapeutics aims to transform obesity treatment by developing precision antibody medicines that target root drivers of metabolic dysfunction and promote long-term weight loss.

Fletcher Biosciences

Fletcher Biosciences is developing precision immunotherapies that selectively target disease-associated immune cells to unlock treatments with best-in-class specificity and safety.

Verto Therapeutics

Verto is developing small molecule translation inhibitors for oncology, advancing programs against Myc and other hard-to-drug targets.

Rho Bio

Rho Bio is developing therapies to restore lymphatic function. Built on discoveries from Yale and WashU, the team includes leading experts in lymphatic biology with an initial focus is on treating neuro-ophthalmic diseases caused by fluid and pressure buildup.

Deck Bio

Deck Bio is developing optimal multi-specific biologics for driving durable efficacy and safety in solid tumors using its proprietary drug discovery platform.

D2B3

Yale spinout D2B3 transiently relaxes the blood brain barrier for drug delivery to the central nervous system.

Aperture Therapeutics

Aperture Therapeutics is developing a new class of medicines mimicking protective gene variants found in resilient individuals to treat neurodegeneration. Their lead drug candidates are oligonucleotides aimed that reversing chronic neuroinflammation in ALS and FTD. The team is also building an in vitro platform to evaluate the impact of diverse human genetics on drug efficacy.

TippingPoint Biosciences

TippingPoint is a spinout from Geeta Narlikar’s lab at UCSF with a drug discovery platform that targets contextual chromatin interactions unique to disease to develop disease-selective small molecule therapeutics.

Nucyrna Therapeutics

NuCyRNA Therapeutics aims to transform RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNAs, starting in neurodegenerative diseases.

Umlaut Bio

Umlaut is an EMBL spinout creating cancer and autoimmune therapeutics trough small molecule inhibition of tRNA modifications that globally dysregulate signaling pathway gene expression.

CloverLeaf Bio

Developing a first in class suite of engineered tRNA therapeutics for oncology, Cloverleaf is a Yale spinout aiming to inhibit tRNA modifying enzymes that are overexpressed in cancer.

Babylon Biosciences

Babylon Biosciences is a small molecule therapeutics company focused on diseases of the nervous system. The company closed an oversubscribed seed round by top tier investors in Q324 and is currently in stealth.

Velocity Bio

Velocity Bio is a Stanford University spin out accelerating allosteric drug discovery with microfluidics for difficult-to-drug enzyme targets.

Bullseye Biosciences

Bullseye Biosciences integrates AI and automation with directed evolution to unlock intracellular protein-protein interaction (PPI) therapeutics, enabling scalable drug discovery for previously undruggable targets.

Integrated Biosciences

Integrated Biosciences combines optogenetics and AI to identify new molecules targeting stress response pathways. The company closed a seed financing in H2’24.